News

On July 26, 2024, Genzyme filed a complaint (“Complaint”) against Sarepta Therapeutics (“Sarepta”) in the District of Delaware. Genzyme Corp. v. Sarepta Therapeutics, Inc., No. 1:24-cv-00882 (D. Del.).  In its complaint, Genzyme alleges that Sarepta infringed Genzyme’s U.S. Patent Nos. 7,704,721 and 9,051,542 (collectively, “the Patents-In-Suit”) by making, using, offering for sale, and/or selling Elevidys® (delandistrogene moxeparvovec-rokl) in the U.S.

Elevidys® is a onetime adeno-associated virus vector-based gene therapy used to treat patients with Duchenne muscular dystrophy (“DMD”) caused by a mutation in the DMD gene.  The Patents-In-Suit recite claims directed to methods for the preparation of compositions for the storage of recombinant adeno-associated virus (rAAV) vector particles in which the particles do not significantly aggregate.

On June 22, 2023, Sarepta obtained FDA approval to market Elevidys® for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. Sarepta then obtained FDA approval on June 20, 2024 for an expanded indication for Elevidys® which includes non-ambulatory DMD patients aged 4 years and older and similarly have a confirmed mutation in the DMD gene. Genzyme alleges that Sarepta has been marketing Elevidys® in the U.S. since obtaining FDA approval in 2023.

Genzyme is seeking, inter alia, a judgment of infringement and willful infringement of the Patents-In-Suit, damages, and reasonable attorneys’ fees, costs, and expenses.

There are currently pending an IPR and several litigations involving Elevidys®See, e.g., Sarepta Therapeutics, Inc. v. Trustees of The University of Pennsylvania, IPR2024-00580 (awaiting Institution Decision); Regenxbio Inc. v. Sarepta Therapeutics, Inc., No. 1:23-cv-00667 (D. Del.) (stayed pending IPR2024-00580); Regenxbio Inc. v. Sarepta Therapeutics, Inc., No. 1:20-cv-01226 (D. Del.) (summary judgment of invalidity, pending Federal Circuit appeal); Wilson Wolf Mfg. Corp. v. Sarepta Therapeutics, Inc., No. 1:19-cv-02316 (D. Del.) (stayed).

In 2023 Elevidys® had U.S. sales of about $200.4 million.

We continue to monitor this case.  For more information on this and other gene therapy and biosimilar litigations, visit BiologicsHQ.com.

_____________________________________________________

The authors would like to thank April Breyer Menon for her contributions to this article.


    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha